Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Tuba Canak-ipek; Meltem Avci-adali; Ceyda Ekentok Atıcı; Emine Şalva; Suna Özbaş

Makale detayları

Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Yazarlar:

Tuba Canak-ipek | Meltem Avci-adali | Ceyda Ekentok Atıcı | Emine Şalva | Suna Özbaş

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Biotechnology

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 1, pp.86-96

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345944

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Clustered regularly interspaced short palindromic repeat CRISPR-associated Cas9 nuclease system CRISPRCas9 has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPRCas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosanCRISPR-Cas9protamine nanoplexes and performed in vitro characterization. The results showed that the chitosanprotamine complex increased the zeta potential of the VEGF CRISPRCas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19 and 30.2 in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosanVEGF CRISPRCas9 plasmidprotamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.

 Clustered regularly interspaced short palindromic repeat CRISPR-associated Cas9 nuclease system CRISPRCas9 has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPRCas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosanCRISPR-Cas9protamine nanoplexes and performed in vitro characterization. The results showed that the chitosanprotamine complex increased the zeta potential of the VEGF CRISPRCas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19 and 30.2 in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosanVEGF CRISPRCas9 plasmidprotamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.

 Clustered regularly interspaced short palindromic repeat CRISPR-associated Cas9 nuclease system CRISPRCas9 has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPRCas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosanCRISPR-Cas9protamine nanoplexes and performed in vitro characterization. The results showed that the chitosanprotamine complex increased the zeta potential of the VEGF CRISPRCas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19 and 30.2 in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosanVEGF CRISPRCas9 plasmidprotamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.

 Clustered regularly interspaced short palindromic repeat CRISPR-associated Cas9 nuclease system CRISPRCas9 has emerged as a powerful toolbox for cancer therapy, serving as a gene fixed-point knock-out method. However, suitable gene carrier systems are urgently needed to encapsulate the CRISPRCas9 system and to improve the uptake into the cancer cells for anti-cancer therapy. In cancer therapy, breast cancer stem cells should be also targeted besides tumor cells. In this study, we prepared chitosanCRISPR-Cas9protamine nanoplexes and performed in vitro characterization. The results showed that the chitosanprotamine complex increased the zeta potential of the VEGF CRISPRCas9 plasmid from negative to positive. In vitro cell culture studies showed that VEGF silencing efficiency was 46.19 and 30.2 in MCF-7 and MCF-7s, respectively, after 7 days. The invasion capacity of cancer cells decreased significantly for both cell types. The results indicate that chitosanVEGF CRISPRCas9 plasmidprotamine complexes can be used to reduce VEGF expression, leading to a decrease in the invasion capacity of breast cancer as well as breast cancer stem cells and providing proof of concept for more advanced studies, including in vivo studies, of this system.

Makale detayları

Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Yazarlar:

Tuba Canak-ipek | Meltem Avci-adali | Ceyda Ekentok Atıcı | Emine Şalva | Suna Özbaş

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Biotechnology

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 1, pp.86-96

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345944

pISSN:

2630-6344

chitosan/protamine

CRISPR-Cas9

VEGF

breast cancer

breast cancer stem cells

Sayı

Makale detayları

Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Yazarlar: Tuba Canak-ipek | Meltem Avci-adali | Ceyda Ekentok Atıcı | Emine Şalva | Suna Özbaş

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Biotechnology

Dergi: Journal of Research in Pharmacy Vol.27 Issue 1, pp.86-96

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001345944

pISSN: 2630-6344

chitosan/protamine

CRISPR-Cas9

VEGF

breast cancer

breast cancer stem cells

Sayı

Yazarlar:

Tuba Canak-ipek | Meltem Avci-adali | Ceyda Ekentok Atıcı | Emine Şalva | Suna Özbaş

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Biotechnology

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 1, pp.86-96

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001345944

pISSN:

2630-6344